Advanced Magnetics To Weigh European Data For Combidex Resubmission
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Advanced Magnetics will consider using clinical trial data generated by its European marketing/development partner Guerbet to respond to a March 2005 FDA "approvable" letter for its molecular imaging agent Combidex (ferumoxtran-10) for use with MRI, the company said.